Ugrás a tartalomra
Global sound
Medical Device Global Market Access

Medical Device Global Market Access

FDA IVD Emerging Pathogens Guidance: Validation for Section 564 Emergencies

· 5 perc

Epizódjegyzetek

On November 9, 2026, the US FDA issued final guidance clarifying validation requirements for In Vitro Diagnostic (IVD) devices targeting emerging pathogens during a Section 564 declared emergency. This episode breaks down the key recommendations for manufacturers, including expectations for analytical and clinical validation, the use of contrived samples, and the impact on future Emergency Use Authorization (EUA) submissions. We outline practical steps that IVD companies can take now to align their internal processes with this guidance to ensure they are prepared for the next public health crisis.

Key Questions:
- What are the FDA's new validation expectations for IVD tests during a public health emergency?
- How does the November 9, 2026 guidance affect the Emergency Use Authorization (EUA) process?
- What specific recommendations does the FDA provide for using contrived samples when patient samples are scarce?
- Which types of IVD manufacturers are most impacted by this new guidance?
- What are the minimum requirements for analytical validation, such as limit of detection and specificity?
- How does this guidance change the strategy for clinical validation studies for emerging pathogens?
- What are four practical actions your regulatory team should take to prepare for these new requirements?
- Why is early engagement with the FDA through pre-EUA submissions more critical now?

Sources:
- https://www.federalregister.gov/documents/2026/11/09/2026-22883/validation-of-certain-in-vitro-diagnostic-devices-for-emerging-pathogens-during-a-section-564
- https://www.fda.gov/news-events/cdrh-new-news-and-updates

How Pure Global can help:
Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements and accelerate market access. Our experts specialize in US FDA submissions, including Emergency Use Authorizations (EUAs) and pre-submission strategies. We can help you develop robust validation plans that align with the latest FDA guidance, prepare comprehensive technical dossiers, and manage communications with the agency to ensure a smooth review process. To learn how we can support your global market access goals, visit us at https://pureglobal.com or contact us at [email protected]. Explore our free AI-powered regulatory tools and device database at https://pureglobal.ai.

Weboldal: pureglobal.com

Élőben, az elmúlt órában: 10 872 dal, 4 584 állomás, 116 ország

Fedezd fel a világot a rádión keresztül

További felfedezési lehetőségek (7)

Hallottál valami jót? Mentsd el, vagy nyisd meg rögtön a Spotifyban.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
FIERAMIX LA MEXICANAHallgatás folytatása